References
1. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C.
Probable Molecular Mechanism of Remdesivir for the Treatment of
COVID-19: Need to Know More. Arch Med Res 2020; 51: 585-86.
2. Bukreyeva N, Sattler RA, Mantlo EK, Wanninger T, Manning JT, Huang C,
Paessler S, Zeldis JB. The IMPDH inhibitor merimepodib provided in
combination with the adenosine analogue remdesivir reduces SARS-CoV-2
replication to undetectable levels in vitro. F1000Research 2020; 9: 361.
3. Malin JJ, Suarez I, Priesner V, Fatkenheuer G, Rybniker J. Remdesivir
against COVID-19 and Other Viral Diseases. Clin Microbiol Rev 2020; 34.
4. Afshar ZM, Babazadeh A, Javanian M, Barary M, Rekha VVK, Ebrahimpour
S. A comprehensive review of COVID-19 treatment. Acta facultatis medicae
Naissensis 2021; 38: 105-15.
5. Tchesnokov EP, Feng JY, Porter DP, Gotte M. Mechanism of Inhibition
of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses 2019;
11: 326.
6. Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard
AL, Flint M, McMullan LK, Siegel D, Clarke MO, Mackman RL, Hui HC,
Perron M, Ray AS, Cihlar T, Nichol ST, Spiropoulou CF. GS-5734 and its
parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.
Sci Rep 2017; 7: 43395.
7. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB,
Leist SR, Pyrc K, Feng JY, Trantcheva I. Broad-spectrum antiviral
GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science
translational medicine 2017; 9.
8. Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML,
Leist SR, Schafer A, Dinnon KH, 3rd, Stevens LJ, Chappell JD, Lu X,
Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR,
Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A,
Thornburg NJ, Swanstrom R, Denison MR, Baric RS. An orally bioavailable
broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial
cell cultures and multiple coronaviruses in mice. Sci Transl Med 2020;
12.
9. Ferner RE, Aronson JK. Remdesivir in covid-19. BMJ 2020; 369: m1610.
10. Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli
A, Berrino L, Racagni G, Rossi F, Capuano A. Current pharmacological
treatments for COVID-19: What’s next? Br J Pharmacol 2020; 177: 4813-24.
11. Kokic G, Hillen HS, Tegunov D, Dienemann C, Seitz F, Schmitzova J,
Farnung L, Siewert A, Hobartner C, Cramer P. Mechanism of SARS-CoV-2
polymerase stalling by remdesivir. Nat Commun 2021; 12: 279.
12. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP,
Gotte M. Remdesivir is a direct-acting antiviral that inhibits
RNA-dependent RNA polymerase from severe acute respiratory syndrome
coronavirus 2 with high potency. J Biol Chem 2020; 295: 6785-97.
13. Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J, Patel
NR, Klena JD, Nichol ST, Cihlar T, Zaki SR, Feldmann H, Spiropoulou CF,
de Wit E. Remdesivir (GS-5734) protects African green monkeys from Nipah
virus challenge. Sci Transl Med 2019; 11.
14. Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible
therapeutic option for the COVID-19. Travel medicine and infectious
disease 2020; 34: 101615.
15. Aleissa MM, Silverman EA, Paredes Acosta LM, Nutt CT, Richterman A,
Marty FM. New perspectives on antimicrobial agents: remdesivir treatment
for COVID-19. Antimicrobial agents and chemotherapy 2021; 65: e01814-20.
16. Health NIo. Chloroquine or Hydroxychloroquine and/or Azithromycin.
In: COVID-19 Treatment Guidelines, Therapies: Antiviral Therapy National
Institutes of Health, 2021.
17. Dölken L, Stich A, Spinner CD. Remdesivir for Early COVID-19
Treatment of High-Risk Individuals Prior to or at Early Disease
Onset—Lessons Learned. Viruses 2021; 13: 963.
18. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu
Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang
Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan
G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin
H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in
adults with severe COVID-19: a randomised, double-blind,
placebo-controlled, multicentre trial. Lancet 2020; 395: 1569-78.
19. Wong CKH, Lau KTK, Au ICH, Xiong X, Lau EHY, Cowling BJ. Clinical
improvement, outcomes, antiviral activity, and costs associated with
early treatment with remdesivir for patients with COVID-19. Clin Infect
Dis 2021.
20. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC,
Hohmann E, Chu HY, Luetkemeyer A, Kline S. Remdesivir for the treatment
of Covid-19. New England Journal of Medicine 2020; 383: 1813-26.
21. Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T.
Remdesivir for treatment of COVID-19; an updated systematic review and
meta-analysis. Eur J Pharmacol 2021; 897: 173926.
22. Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: A
critical review of pharmacology, pre-clinical and clinical studies.
Diabetes Metab Syndr 2020; 14: 641-48.
23. Hillaker E, Belfer JJ, Bondici A, Murad H, Dumkow LE. Delayed
Initiation of Remdesivir in a COVID-19-Positive Patient. Pharmacotherapy
2020; 40: 592-98.
24. Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C, Pagani G,
Gubertini G, Coen M, Magni C, Castelli A, Borghi B, Colombo R, Giorgi R,
Angeli E, Mileto D, Milazzo L, Vimercati S, Pellicciotta M, Corbellino
M, Torre A, Rusconi S, Oreni L, Gismondo MR, Giacomelli A, Meroni L,
Rizzardini G, Galli M. Compassionate remdesivir treatment of severe
Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients:
Clinical outcome and differences in post-treatment hospitalisation
status. Pharmacol Res 2020; 158: 104899.
25. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner
CD, Galli M, Ahn MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi
AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Munoz J,
Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A, Investigators
G-U-. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N
Engl J Med 2020; 383: 1827-37.
26. Ippolito M, Cortegiani A. Length of remdesivir treatment in patients
with severe COVID-19. Breathe (Sheff) 2021; 17: 200276.
27. Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech AM, Lane C,
Lundgren J. Persistent COVID-19 in an Immunocompromised Patient
Temporarily Responsive to Two Courses of Remdesivir Therapy. J Infect
Dis 2020; 222: 1103-07.
28. Hoon Baang J, Smith C, Mirabelli C. Prolonged SARS-CoV-2 replication
in an immunocompromised patient. J Inf Dis 2020; 223: 23-27.
29. Zhai G, Li M, Wang Y, Wu J. Drug-Induced Liver Disturbance During
the Treatment of COVID-19. Front Pharmacol 2021; 12: 719308.
30. Team C-I. Clinical and virologic characteristics of the first 12
patients with coronavirus disease 2019 (COVID-19) in the United States.
Nat Med 2020; 26: 861-68.
31. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt
T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan
E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D,
Chihara S, Cohen SH, Cunningham J, D’Arminio Monforte A, Ismail S, Kato
H, Lapadula G, L’Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M,
Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y,
Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I,
Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A,
Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of
Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020; 382:
2327-36.
32. Godeau D, Petit A, Richard I, Roquelaure Y, Descatha A.
Return-to-work, disabilities and occupational health in the age of
COVID-19. Scand J Work Environ Health 2021; 47: 408-09.
33. Li X, Liu R, Cui Y, Liang J, Bi Z, Li S, Miao Y, Zhang L, Li X, Zhou
H, Yang C. Protective Effect of Remdesivir Against Pulmonary Fibrosis in
Mice. Front Pharmacol 2021; 12: 692346.
34. Nabati M, Parsaee H. Potential Cardiotoxic Effects of Remdesivir on
Cardiovascular System: A Literature Review. Cardiovasc Toxicol 2021:
1-5.
35. Mulangu S, Dodd LE, Davey RT, Jr., Tshiani Mbaya O, Proschan M,
Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali
R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ,
Group PW, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao
H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier
I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett
K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood
J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W,
Gettinger N, Vallee D, Nordwall J, Team PCS. A Randomized, Controlled
Trial of Ebola Virus Disease Therapeutics. N Engl J Med 2019; 381:
2293-303.
36. Hopkins BJ, Prokesch BC. Anaphylaxis due to remdesivir.
Antimicrobial agents and chemotherapy 2021; 65: e00233-21.
37. van Laar SA, de Boer MGJ, Gombert-Handoko KB, Guchelaar HJ,
Zwaveling J, group LU-C-r. Liver and kidney function in patients with
Covid-19 treated with remdesivir. Br J Clin Pharmacol 2021; 87: 4450-54.
38. McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review
of Early and Emerging Options. Open Forum Infect Dis 2020; 7: ofaa105.
39. Zhou SF. Drugs behave as substrates, inhibitors and inducers of
human cytochrome P450 3A4. Curr Drug Metab 2008; 9: 310-22.
40. Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI,
Rubio-García A, Torelló-Iserte J, Crespo-Facorro B. Drug-drug
interactions between COVID-19 treatments and antipsychotics drugs:
integrated evidence from 4 databases and a systematic review.
Psychopharmacology 2021; 238: 329-40.
41. Bishara D, Kalafatis C, Taylor D. Emerging and experimental
treatments for COVID-19 and drug interactions with psychotropic agents.
Ther Adv Psychopharmacol 2020; 10: 2045125320935306.
42. Fan Q, Zhang B, Ma J, Zhang S. Safety profile of the antiviral drug
remdesivir: An update. Biomed Pharmacother 2020; 130: 110532.
43. Adamsick ML, Gandhi RG, Bidell MR, Elshaboury RH, Bhattacharyya RP,
Kim AY, Nigwekar S, Rhee EP, Sise ME. Remdesivir in Patients with Acute
or Chronic Kidney Disease and COVID-19. J Am Soc Nephrol 2020; 31:
1384-86.
44. Aiswarya D, Arumugam V, Dineshkumar T, Gopalakrishnan N, Lamech TM,
Nithya G, Sastry BV, Vathsalyan P, Dhanapriya J, Sakthirajan R. Use of
remdesivir in patients with COVID-19 on hemodialysis: a study of safety
and tolerance. Kidney international reports 2021; 6: 586-93.
45. Umemura T, Nishikawa K, Mutoh Y, Sasano H, Kozaki K, Yamada T,
Ichihara T. Usage experience of remdesivir for SARS-CoV-2 infection in a
patient with chronic cirrhosis of Child-Pugh class C. J Antimicrob
Chemother 2021; 76: 1947-48.
46. Bertolini A, van de Peppel IP, Bodewes F, Moshage H, Fantin A,
Farinati F, Fiorotto R, Jonker JW, Strazzabosco M, Verkade HJ, Peserico
G. Abnormal Liver Function Tests in Patients With COVID-19: Relevance
and Potential Pathogenesis. Hepatology 2020; 72: 1864-72.
47. Soman SO, Raveendran A. Remdesivir and Favipiravir for COVID-19: An
update. Annals of Clinical Cardiology 2020; 2: 51.
48. Sabers AJ, Williams AL, Farley TM. Use of remdesivir in the presence
of elevated LFTs for the treatment of severe COVID-19 infection. BMJ
Case Reports 2020; 13: e239210.
49. Agarwal A, Chen A, Ravindran N, To C, Thuluvath PJ. Gastrointestinal
and Liver Manifestations of COVID-19. J Clin Exp Hepatol 2020; 10:
263-65.
50. Cheng P, Zhu H, Witteles RM, Wu JC, Quertermous T, Wu SM, Rhee JW.
Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and
Areas of Uncertainty. Curr Cardiol Rep 2020; 22: 34.
51. Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target
of SARS-CoV-2? Am J Physiol Renal Physiol 2020; 318: F1454-F62.
52. Ganesh SY, Nachimuthu N. Treatment experience with inhaled
corticosteroids in combination with remdesivir and dexamethasone among
COVID-19 Patients admitted to a rural community hospital: A case series.
Cureus 2020; 12.
53. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V,
Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh
R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader
AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri
A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC,
Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E,
Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I,
Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini
N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML,
Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR,
Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N,
Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H,
Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 -
Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384: 497-511.
54. Chappell L, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell
L, Staplin N, Brightling C, Ustianowski A. Dexamethasone in hospitalized
patients with Covid-19-preliminary report. The New England Journal of
Medicine 2020; 384: 693-704.
55. Benfield T, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C,
Israelsen SB, Jensen J, Jensen TØ, Johansen IS. Improved Survival Among
Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated
With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort
Study. Clinical Infectious Diseases: An Official Publication of the
Infectious Diseases Society of America 2021: ciab536.
56. Martinez DR, Schaefer A, Leist SR, Gully K, Feng JY, Bunyan E,
Porter DP, Cihlar T, Montgomery SA, Baric RS. Prevention and therapy of
SARS-CoV-2 and the B.1.351 variant in mice. bioRxiv 2021.
57. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan
V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM,
Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC,
Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo
B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES,
Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael
NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M,
Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski
M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W,
Nayak SU, Dodd LE, Beigel JH, Members A-SG. Baricitinib plus Remdesivir
for Hospitalized Adults with Covid-19. N Engl J Med 2021; 384: 795-807.
58. Ohl ME, Miller DR, Lund BC, Kobayashi T, Miell KR, Beck BF,
Alexander B, Crothers K, Sarrazin MSV. Association of Remdesivir
Treatment With Survival and Length of Hospital Stay Among US Veterans
Hospitalized With COVID-19. JAMA Network Open 2021; 4: e2114741.
59. Dyer O. Covid-19: Remdesivir has little or no impact on survival,
WHO trial shows. BMJ 2020; 371: m4057.
60. Singh S, Khera D, Chugh A, Khera PS, Chugh VK. Efficacy and safety
of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and
meta-analysis. BMJ Open 2021; 11: e048416.
61. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E,
Pardo-Hernandez H, Qasim A, Martinez JPD, Rochwerg B, Lamontagne F, Han
MA, Liu Q, Agarwal A, Agoritsas T, Chu DK, Couban R, Cusano E, Darzi A,
Devji T, Fang B, Fang C, Flottorp SA, Foroutan F, Ghadimi M,
Heels-Ansdell D, Honarmand K, Hou L, Hou X, Ibrahim Q, Khamis A, Lam B,
Loeb M, Marcucci M, McLeod SL, Motaghi S, Murthy S, Mustafa RA, Neary
JD, Rada G, Riaz IB, Sadeghirad B, Sekercioglu N, Sheng L, Sreekanta A,
Switzer C, Tendal B, Thabane L, Tomlinson G, Turner T, Vandvik PO,
Vernooij RW, Viteri-Garcia A, Wang Y, Yao L, Ye Z, Guyatt GH,
Brignardello-Petersen R. Drug treatments for covid-19: living systematic
review and network meta-analysis. BMJ 2020; 370: m2980.
62. Yang C-J, Wei Y-J, Chang H-L, Chang P-Y, Tsai C-C, Chen Y-H, Hsueh
P-R. Remdesivir use in the coronavirus disease 2019 pandemic: A
mini-review. Journal of Microbiology, Immunology and Infection 2020; 54:
27-36.
63. Bansal V, Mahapure KS, Bhurwal A, Gupta I, Hassanain S, Makadia J,
Madas N, Armaly P, Singh R, Mehra I, O’Horo JC, Kashyap R. Mortality
Benefit of Remdesivir in COVID-19: A Systematic Review and
Meta-Analysis. Front Med (Lausanne) 2020; 7: 606429.
64. Alegre-Del Rey EJ, Gil-Sierra MD, Alarcon de la Lastra-Romero C,
Sanchez-Hidalgo M. Remdesivir and mortality reduction in COVID-19
patients: a systematized subgroup analysis of clinical trials. Farm Hosp
2021; 45: 28-31.
65. Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS,
Wang S, Walunas TL, Swaminathan S, Slim J, Chin B, De Wit S, Ali SM,
Soriano Viladomiu A, Robinson P, Gottlieb RL, Tsang TYO, Lee IH,
Haubrich RH, Chokkalingam AP, Lin L, Zhong L, Bekele BN, Mera-Giler R,
Gallant J, Smith LE, Osinusi AO, Brainard DM, Hu H, Phulpin C, Edgar H,
Diaz-Cuervo H, Bernardino JI. Remdesivir for Severe COVID-19 versus a
Cohort Receiving Standard of Care. Clin Infect Dis 2020.
66. Mahase E. Covid-19: US approves remdesivir despite WHO trial showing
lack of efficacy. Bmj 2020; 371: m4120.
67. Spinner CD, Gottlieb RL, Criner GJ, López JRA, Cattelan AM,
Viladomiu AS, Ogbuagu O, Malhotra P, Mullane KM, Castagna A. Effect of
remdesivir vs standard care on clinical status at 11 days in patients
with moderate COVID-19: a randomized clinical trial. Jama 2020; 324:
1048-57.
68. Lin HXJ, Cho S, Meyyur Aravamudan V, Sanda HY, Palraj R, Molton JS,
Venkatachalam I. Remdesivir in Coronavirus Disease 2019 (COVID-19)
treatment: a review of evidence. Infection 2021; 49: 401-10.
69. McCreary EK, Angus DC. Efficacy of Remdesivir in COVID-19. JAMA
2020; 324: 1041-42.